WO2019117491A1 - Aromatic composition for suppressing urge to smoke and preparation method therefor - Google Patents

Abstract

The present invention is characterized by comprising: an Acorus Gramineus root/stem extract contained in a proportion of 30-36 wt%; Angelicae Gigantis Radix contained in a proportion of 15-18 wt%; a Polygala Tenuifolia root extract contained in a proportion of 15-18 wt%; Agastache rugosa added in a proportion of 15-18 wt%; and St John's Wort added in a proportion of 15-18 wt%.

Description

Aromatic composition for smoking cessation suppression and method for producing the same

The present invention relates to a perfume composition for inhibiting smoking cigarettes and a method for producing the same, and more particularly, to a perfume composition for smoking cigarettes which suppresses the development of hyperactivity that occurs during smoking cessation only by taking a fragrance without taking or inhaling, Depression, depression, obsessive-compulsive disorder, dementia, Alzheimer's disease, Red syndrome, Huntington's disease, anorexia nervosa, bulimia, and brain metastasis and can reduce the time and cost of manufacturing a composition for smoking cessation suppression And to a method for producing the same.

In general, the proportion of tobacco products among the harmful substances of human health is increasing.

Research into the relationship between smoking and disease outbreaks has been intensively researched since the mid-1900s, and evidence of increased incidence of lung cancer and other health problems, as well as evidence of other health problems, is continuing to accumulate. Actually, cigarette smoke consists of mainstream smoke and sidestream smoke, and mainstream smoke is smoke after smokers drink, and sidestream smoke is smokestack smoke from the end of a burning cigarette.

About 4,000 kinds of tobacco smoke were analyzed. About 4,000 kinds of tobacco smoke constitutes about 95% of the total weight of mainstream smoke, and the remaining thousands of components are present in an extremely small amount.

Cigarette smoke is caused by incomplete combustion of cigarette. Water and carbon dioxide are generated when it is completely burned. Incomplete combustion is caused by incomplete combustion of some tobacco leaf components, insufficient oxygen supply, distillation, sublimation, pyrolysis, , And volatility.

The cigarette smoke is aerosol, which is a mixture of liquid and fine particles mixed in a gas. The filter is a Cambridge glass fiber filter (filter with a filter efficiency of 99% or more of particles having a particle diameter of 0.1 μm or more) ) Is referred to as a gas or vapor component.

The gas or vapor components consist of nitrogen (59%), oxygen (13.4%), carbon dioxide (13.5%) and carbon monoxide (3.2%) and are toxic to the bronchial ciliary processes such as aldehydes, ketones, alcohols and esters Volatile components having a low molecular weight are included.

In addition, substances that are filtered by glass fiber glass filters are called particulate phase components, which are about 8% of tobacco smoke, at least 38 known carcinogens, including tar, carcinogens and nicotine , And other inorganic and organic chemicals.

However, recent studies have shown that even in the 21st century, cigarettes are still expected to remain the greatest risk factor for human health, but nonetheless it is not easy for cigarette lovers to break the habit of smoking, There is a problem that nicotine and tar components are accumulated in the body due to tobacco smoke.

To solve the above problem, a functional beverage for suppressing smoking needs has been developed. The functional beverage for suppressing smoking needs according to the prior art contains 500 ml of mineral-containing water and 70% by weight of natural peppermint 1% by weight of Eucalyptus oil, 5% by weight of L-menthol, 20% by weight of propylene glycol, 2% by weight of tobacco leaf extract and 1% by weight of 1 The tea contains 0.3 ml of a milky lotion consisting of Casing and 1% by weight of Top Dressing.

BACKGROUND ART [0002] The background art of the present invention is disclosed in Korean Patent Laid-Open Publication No. 10-2006-0084409 (published on Jul. 24, 2006, entitled " Functional beverage for suppressing smoking needs and method for producing the same).

The functional drink for smoking suppression according to the prior art has a problem that the user has to drink the functional beverage and the smoking need is suppressed so that the user must carry it or store it and drink it.

Therefore, there is a need for improvement.

The present invention relates to a method for suppressing the development of hyperactivity in smoking cessation by taking a fragrance without taking or inhaling it, The present invention provides a perfume composition for smoking cessation suppression which can alleviate withdrawal symptoms such as anorexia nervosa, bulimia and brain metastasis, and can reduce the time and cost required for manufacturing a composition for inhibiting smoking cessation and a method for producing the same. .

The present invention relates to a composition comprising Acorus Gramineus Root / Stem Extract in an amount of 30 to 36% by weight, Angelicae Gigantis Radix in a proportion of 15 to 18% by weight, and 15 to 18% (Polygala Tenuifolia Root Extract), Agastache rugosa added at a ratio of 15 to 18 wt%, and St John's Wort added at a ratio of 15 to 18 wt%.

The fragrance composition of the present invention, which comprises the granules of the present invention, the Angelica gigas Nakai, the raw paper, the granules, the granules, and the granules of the present invention, is characterized by inhibiting hyperactivity reaction that occurs when the user is exposed to nicotine during smoking cessation .

The fragrance composition of the present invention, which comprises the granules of the present invention, the Angelica gigas Nakai, the raw paper, the granules, the granules, and the blossoms, increases Brain-Derived Neurotrophic Factor (BDNF) Thereby alleviating the symptoms.

The present invention also relates to a method for preparing a mixture comprising: (a) metering and pulverizing and mixing the seeds of Chinese persimmon, Angelica gigas Nakai, Chinese cabbage, Chinese cabbage, Chinese cabbage, and Chinese cabbage to provide a mixture; (b) filtering and filtering the mixture to a first set size; (c) extracting the supercritical oil for 7 to 9 hours at a pressure of 350 to 450 bar and a temperature of 55 to 65 캜; (d) cooling the supercritical oil at room temperature after allowing the supercritical oil to boil for 20 to 40 minutes at a temperature of 45 to 55 DEG C; (e) filtering and filtering at a second set size; And (f) filtering through a third set size and then passing through a paper filter to perform double filtration.

The perfume composition for smoking cessation suppression according to the present invention and the method for producing the same according to the present invention are manufactured from a composition including Seocheongpo, Angelica gigas Nakai, Wonji, (BDNF) expression, thereby alleviating nicotine withdrawal symptoms such as depression, epilepsy, obsessive compulsive disorder, dementia, Alzheimer's disease, Red syndrome, Huntington's disease, anorexia nervosa, bulimia and brain metastasis There is an advantage that can be made.

Further, since the fragrance composition for smoking cessation suppression according to the present invention and the preparation method thereof are manufactured from a fragrance composition including Seocheongpo, Dangwoo, Chungwoo, Kwakyoung, and Sungnyogi, It is not necessary to provide a separate storage container for one dose, and it is advantageous in that the time and cost required for storage and packaging of the composition for suppressing desorption needles can be reduced.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a first graph showing an effect of suppressing hyperactivity by a smoking article-controlling perfume composition according to an embodiment of the present invention. FIG.

FIG. 2 is a second graph showing an effect of inhibiting hyperactivity by a smoking article-controlling perfume composition according to an embodiment of the present invention.

FIG. 3 is a graph showing the result of brain-derived neurophysiological expression by a smoking article-controlling perfume composition according to an embodiment of the present invention.

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, one embodiment of a smoking article-controlling perfume composition and a method for producing the same according to the present invention will be described with reference to the accompanying drawings.

In this process, the thicknesses of the lines and the sizes of the components shown in the drawings may be exaggerated for clarity and convenience of explanation.

In addition, the terms described below are terms defined in consideration of the functions of the present invention, which may vary depending on the intention or custom of the user, the operator.

Therefore, definitions of these terms should be made based on the contents throughout this specification.

FIG. 1 is a first graph showing an effect of suppressing hyperactivity by a smoking article-suppressing perfume composition according to an embodiment of the present invention, and FIG. 2 is a graph showing the effect of a smoking article-suppressing perfume composition according to an embodiment of the present invention FIG. 3 is a graph showing the brain-derived neurophysiologic expression results of the smoking need suppressing perfume composition according to an embodiment of the present invention. FIG.

1 to 3, the fragrance composition for smoking suppression according to an embodiment of the present invention comprises Acorus Gramineus Root / Stem Extract in a proportion of 30 to 36 wt%, 15 to 18 wt% Angelicae Gigantis Radix, which is contained in a proportion of 15 to 18% by weight, Polygala Tenuifolia Root Extract which is contained in a proportion of 15 to 18% by weight, Agastache rugosa, which is added in a proportion of 15 to 18% % ≪ / RTI > of St John's Wort.

Seokchangpo is a perennial plant with green leaves in each season. Rootstocks are thick and hard and have many nodes. They live on the same spot as a rock gap with their roots.

Narrow strips are brittle and shiny. The end of the leaf is pointed like a knife, the edge is flat and always gives a good fragrance. The flower blossoms in the shape of a round stick in the middle part of the flower with the appearance like a leaf. The length of the flower stick is 5cm and the color is yellow Blue.

It contains 0.5 ~ 0.8% essential oil in the rootstock. Its components are Asaron, Palmitinsaure, Phenol, etc. It regulates respiration and smoothes blood circulation. And it has the effect of dryness, humidification, and extinction.

Applied diseases are used to treat symptoms that are very frustrating, mental, amnesia, and epilepsy. They are used for indigestion, stomach pain, stomach cramps, malaise, bruises, red eyes and red blood.

Angelica is a medicinal substance that stimulates the blood flow of the coronary arteries and stimulates red blood cell generation.

Raw wax is a perennial plant of the dicotyledonous plant rootstock, and its roots are used as expectorant, tonic, or ganjeongje. It is distributed in the north of central Korea and northern China.

Gwakyeong is a medicinal preparation made from the ground of Agastache rugosa (Fisc.r et Mey.) Kuntze. It treats abdominal cavity, anorexia, nausea, vomiting, diarrhea, It is effective for the accompanied cold, vomiting, diarrhea, halitosis, numbness or swelling due to summer diaper, pharmacological action, skin fungi, Escherichia coli, Disease, Pneumococcus, hemolytic streptococcal inhibition and gastric secretion promoting action.

It is one of the herbs originating from Europe and West Asia, and its main components are essential oil, hypericin, hyperforin, flavin, and tannin. It is made with herbal tea for the purpose of treating insomnia, relieving stress, etc., and it is possible to see effects such as astringent action, antibacterial action, and anti-inflammatory action when the flower is oiled and then externalized.

After the materials having the above-mentioned effects are pulverized and mixed, the supercritical oil is extracted, and the mixture is heated with a hot water bath to perform filtration work for 3 to 4 times and cooled to form a perfume composition.

The fragrance composition of the present invention, which includes Seokchangpo, Angelica gigas Nakai, Wonji, Kwakageo, and Seongjaek, has the effect of inhibiting the hyperactivity reaction that occurs when the user is exposed to nicotine during smoking cessation, (Brain-Derived Neurotrophic Factor (BDNF)), which is known to inhibit withdrawal symptoms.

Therefore, if the perfume composition according to the present embodiment is provided in a space in which a user who has begun smoking cessation lives, the fragrance can be used to suppress the hyperactivity reaction and withdrawal caused by smoking cessation, thereby helping to quit smoking.

The perfume composition for suppressing smoking needs according to an embodiment of the present invention and the method of manufacturing the same will be described below.

A method for producing a smoking article-suppressing perfume composition according to an embodiment of the present invention comprises the steps of measuring and pulverizing and mixing in the amounts of Seokchangpo, Angelica gigas, Angelica keiskei, Filtering the mixture and extracting the supercritical oil for 7 to 9 hours while maintaining the mixture at a pressure of 350 to 450 bar and a temperature of 55 to 65 DEG C and a supercritical oil at 45 to 55 DEG C Maintaining the temperature for 20 to 40 minutes and then cooling at room temperature; filtering and filtering at a second set size; and filtering at a third set size, .

First, 33.6 wt% of seaweed, 16.6 wt% of Angelica gigas, 16.6 wt% of raw paper, 16.6 wt% of wort, and 16.6 wt% of freezing water were pulverized and mixed to form a mixture, Filter by 100 meshes.

Subsequently, the supercritical oil is extracted by heating at a pressure of 400 bar and a temperature of 60 DEG C for about 8 hours, and the supercritical oil is allowed to cool to room temperature at a temperature of 50 DEG C for about 30 minutes .

The hot water provided in the above process was passed through a 200 mm filter pater to perform primary filtration of the oil layer, followed by secondary filtration through a 400 mm filter paper, followed by filtration through a paper filter to produce a fragrance composition do.

The above-described fragrance composition may be sprayed into the room while being kept in a liquid state in a liquid state at a predetermined time interval, dried in powder, and placed at a position where air is easily conveyed to provide a fragrance.

It will be apparent to those skilled in the art that various modifications and changes may be made therein without departing from the spirit and scope of the invention.

Experiments to verify the effect of the perfume composition according to the present embodiment were conducted by Samyoung University's industry-academia cooperation corporation, and the contents of the experiment will be described in detail by the following experimental methods.

1. Experimental animals

The experimental animals used in this experiment were purchased from 6-week-old ICR male mice from Samtaco. Experimental rats were grouped in groups of 9 mice per each experimental group for 12 weeks at a temperature of 25 ℃ and humidity of 60% for one week. Experimental animals provided natural access to food and water and provided plenty of prey and food before the start of the experiment.

2. Experimental Sample

In order to treat the sample of No Smoking in accordance with the present embodiment, an isolated cage capable of sufficiently absorbing the fragrance was used. A No Smoking sample was placed in a container that did not interfere with the emission of the fragrance, and then fixed on an experimental animal cage to keep the fragrance flowing freely.

Each experimental animal was then placed in a cage and the top was covered with a filter-mounted lid to minimize the loss of aroma and other caging effects. The animals were allowed to inhale the fragrance of the No Smoking sample for 1 hour at the same time every day during the experiment. Those who did not treat aroma therapy were kept for 1 hour under the same conditions.

3. Experimental method (first experiment - efficacy evaluation test)

1) Locomotor activity.

In order to quantify the activity of experimental animals, we measured video activity using Image J in video. The movement of the animals was monitored in a black acrylic box of 48 cm × 48 cm × 40 cm in height and width.

The images obtained from the digital camera installed on about 2 meters in 9 boxes are transferred to the computer and the center point of the image of the white laboratory animal is recognized per second using the control principle of the white object on the black background, The data were tracked and the distance was quantified.

2) Experimental procedure

The sensitization phase, which treats nicotine hydrogen tartrate (0.4 mg / kg, sc; Sigma, St. Louis, MO) twice consecutively for 7 days twice a day and withdrawal phase of withdrawal of nicotine for 3 days phase), and a testing phase that treated the same dose of nicotine once the day after the withdrawal period (testing phase).

The control group received repeated doses of saline (0.5 ml / kg, s.c.) to determine whether behavioral sensitization, represented by a gradual increase in activity by repeated treatment of nicotine, occurred. Treatment of the drug (No Smoking) started from the start of the experiment.

3) Developmental stage

The animals were transferred from the kennel to the labs where the external noise was blocked and placed individually in 9 activity measurement boxes. Rats were allowed to scent for 60 minutes in an Isolation cage that saturates the fragrance sufficiently. After an adaptation period of 60 minutes in an acrylic box, baseline was again measured for 60 minutes. After the measurement, nicotine (0.4 mg / kg, s.c.) was administered followed by 60 minutes of after treatment.

4) Configuration of experiment group

In the normal group, the experimental animals were administered physiological saline continuously for 7 days twice a day for 2 days, physiological saline was administered on the 11th day for 3 days, and the control group Nicotine is administered seven times a day, followed by a 3-day drug withdrawal period, followed by nicotine on day 11, and the change in activity is administered. After 60 minutes of inhalation, the baseline activity was measured and the behavior change was measured 60 minutes after administration of nicotine.

4. Experimental method (Second experiment - Study on drug efficacy mechanism)

1) Experimental procedure

The second experiment was designed to explore the mechanism by which drug efficacy was revealed. The subjects were classified into the same group as those in which the drug was inhaled for 1 hour daily (No Smoking) and those kept for 1 hour in the same environment. Each group was divided into four groups: (Control group, aroma therapy group, control group + nicotine group, aroma therapy group + nicotine group) were divided into four groups (nicotine and saline group). Baseline levels of nicotine were measured on the third day after the administration of nicotine, and then the cerebral hippocampus was harvested and frozen for further experiments.

2) RNA extraction

Total RNA was extracted from tissues using the TRIzol method to identify changes in gene expression. The extracted hippocampus tissue was taken and added to the Trizol solution. After the addition, chloroform was added, and the mixture was thoroughly mixed and centrifuged at 12,000 × g for 15 minutes at 4 ° C. The supernatant was then mixed with isopropanol and centrifuged at 4 ° C and 12,000xg for 15 minutes. After removing the supernatant, 75% DEPC-treated water was added and centrifuged at 7,500xg for 5 minutes at 4 ° C. The supernatant was removed and then dried at room temperature for 10 minutes. To the completely dried tube, 50 μl of RNase-Free water was added to dissolve the RNA, and the RNA was stored at -80 ° C.

3) Realtime PCR

The extracted total RNA was synthesized by cDNA using Qiagen's Quantitect ™ RT kit (Qiagen, USA) according to the manufacturer's protocol. 2 μl of gDNA wipeout buffer was added to 12 μl of RNA, followed by reaction at 42 ° C for 2 minutes. Then, 1 μl of reverse transcriptase, 4 μl of RT buffe and 1 μl of RT primer mix were added, reacted at 42 ° C for 15 minutes, and reacted at 95 ° C for 3 minutes. Brain-derived neurotrophic factor (BDNF) mRNA expression was measured in this synthesized cDNA using the QuantiTect ™ SYBR® Green PCR kit according to the manufacturer's protocol. Primer sequences were synthesized as shown in Table 1. The cDNA template (1 μl), the forward and reverse primers (10 μM, 1 μl each), the master mix (10 μl) and the H ₂ O Polymerase was activated for 10 min at 95 ℃. After denaturation at 95 ° C for 10 seconds, annealing at 60 ° C for 15 seconds, and polymerization at 72 ° C for 20 seconds, 40 cycles were repeated and post-polymerization was performed at 72 ° C for 2 minutes.

mRNA	Forward	Reverse
GAPDH	5'-GCC ATT TGC AGT GGC AAA GTG G-3 '	5'-GAT GGG CTT CCC GTT GAT GAC AAG C-3 '
BDNF	5'-TGG CTG ACA CTT TTG AGC ACG TC-3 '	5'-GCT CCA AAG GCA CTT GAC TGC TGA-3 '

Primer Sequence, 5 'to 3', GAPDH, glyceraldehyde 3-phosphate dehydrogenase; BDNF, Brain-derived neurotrophic factor

Analysis was performed using Rotor-gene Q real-time PCR (Qiagen, USA). Gene expression values were calculated based on the ΔΔCT method using the Rotor-gene Q series software 1.7 of the company.

5. Statistical processing

Statistical analysis was performed using SPSS (Ver. 10.1) and ANOVA test and Dunnett's post hoc test. The significance level was set at p <0.05.

Result

1. Measurement results for nicotine sensitization

A nicotine-sensitization phase, a 3-day withdrawal phase of nicotine withdrawal, and a testing phase in which nicotine is administered once the day after the withdrawal period, The results of this study were as follows. First, the effect of nicotine addiction on hyperactivity was investigated.

In the control group treated with saline, the activity was 3,948 ± 685 cm, and the activity level was measured as 5,909 ± 587 cm in the nicotine-treated group after the repeated withdrawal of nicotine and the 3-day withdrawal period on the 11th day. The nicotine group was administered in the same manner as the nicotine group and the nicotine group was inhaled daily. The nicotine group was repeatedly administered three times, followed by the nicotine group on the 11th day after the withdrawal period. The result was 3,987 ± 499 (p <0.05, Fig. 1). There was no statistically significant difference between the two groups. Therefore, it was observed that repeated treatment of No Smoking inhibited nicotine addiction and withdrawal symptoms in nicotine drug addiction model.

The graph shown in FIG. 1 is a graph showing an inhibitory effect of the perfume sample treatment on hyperactivity induced by nicotine poisoning. FIG. 1 is a graph showing the effect of nicotine administration on the 11th day after the administration of nicotine for 3 days, (Results are means ± SEM of the distance, *: p <0.05).

2. Study on mechanism of drug action

In order to investigate the mechanism of action of inhibition of hyperactivity development due to nicotine withdrawal of fragrance therapy sample (No Smoking), fragrance therapy was performed once a day, then on the fourth day after the administration of nicotine, As a result of the measurement of the response, the control group placed in the same environment instead of aroma therapy had activity of 6,718 ± 405 cm, 6,537 ± 545 cm in the aroma therapy group treated with aroma therapy for 4 days, In the control group + nicotine group, the activity was 8,223 ± 646 cm, which was statistically significantly higher than the control group and the aroma therapy group (p <0.05, see FIG. 2)

Nicotine group treated with scent therapy for 4 days and nicotine group administered once on the fourth day showed a statistically significant decrease in activity compared with control group and nicotine group as measured with 6,314 ± 784 cm of activity in the nicotine group (P < 0.05, see Fig. 2)

FIG. 2 shows the result of measuring the moving distance after one dose of nicotine after treating the perfume sample for 4 days in order to examine the action mechanism of the perfume sample (Results are means ± SEM of the distance, *: p <0.05 ).

In order to investigate the mechanism of action of inhibition of hyperactivity development due to nicotine withdrawal of fragrance therapy sample (No Smoking), fragrance therapy was performed once a day, then on the fourth day after the administration of nicotine, (BDNF) mRNA expression was measured and the following results were obtained. The brain-derived neurotrophic factor (BDNF) mRNA expression was measured by measuring the response and extracting the cerebral hippocampal region. As a result of calculating the ratio of BDNF mRNA expression in the control group to 1.00 ± 0.10, it was 1.32 ± 0.12 in the aroma therapy group treated with the aroma therapy for 4 days (p <0.05, see FIG. 3)

On the fourth day, however, the values of 1.03 ± 0.10 and 0.97 ± 0.13 for the nicotine group and the nicotine group for the nicotine group administered once on the fourth day, respectively, were significantly higher No difference could be observed (see Fig. 3).

FIG. 3 shows the result of measuring the brain-derived neurotrophic factor (BDNF) mRNA expression in the cerebral hippocampal region after the perfume sample was treated for 3 days to examine the action mechanism of the perfume sample (Results are means ± SEM, *: p <0.05)

The BDNF observed in this study is a protein in brain cells produced by the BDNF gene. It is closely related to basic nerve growth and is closely related to the pathological changes due to its deficiency and excess, and is associated with depression, , Dementia, Alzheimer's disease, Rett syndrome, Huntington's disease, anorexia nervosa, bulimia, and epilepsy.

The relationship between the amount of BDNF and the antidepressant effect, especially in relation to depression, is well known. Currently, buprenopine, approved as a non-smoking drug in clinical trials, is known to relieve symptoms such as nervousness withdrawal, nicotine withdrawal symptoms, depression, anxiety, headache, thirst, diminished concentration and digestive disorder.

In this experiment, the efficacy of the aroma therapy sample (No Smoking) for abstinence of nicotine withdrawal was evaluated to evaluate the efficacy of withdrawal of the animal, The amount of BDNF expression in the cerebral hippocampal volume was measured after aroma therapy was conducted to investigate the mechanism of action for the withdrawal of withdrawal symptoms due to nicotine withdrawal from smoking cessation suppression material (No Smoking). As a result, it was confirmed that BDNF expression was significantly increased statistically. In addition, studies on the action pathway in which perfume sample treatment increased BDNF expression should be studied in the future. Based on the results of this study, aroma therapy sample (Smoking No Smoking) And the nicotine withdrawal symptoms were alleviated.

Thus, it is possible to suppress the development of hyperactivity, which is caused by smoking cessation, only by taking a fragrance without taking or inhaling it, and it is possible to suppress the development of hyperactivity caused by smoking cessation, and to prevent depression, cognitive impairment, obsessive compulsive disorder, dementia, Alzheimer's disease, Red syndrome, Huntington's disease, It is possible to provide a perfume composition for smoking cessation suppression which can alleviate withdrawal symptoms such as depression, bulimia, bulimia, and brain metastasis, and can reduce time and cost required for manufacturing a composition for suppressing smoking needs and a method for manufacturing the same.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. .

The perfume composition for suppressing smoking needs and the method for producing the perfume composition of the present invention have been described by way of example. However, the perfume composition of the present invention and the method for producing the perfume composition of the present invention are also applicable to other products other than the perfume composition for controlling smoking needs Can be used.

Accordingly, the true scope of the present invention should be determined by the following claims.

Claims (4)

1. (Angelicae Gigantis Radix), which is contained in a proportion of 15 to 18% by weight, and polygala (Polygala), which is contained in a proportion of 15 to 18% by weight, Tenuifolia Root Extract), Agastache rugosa added at a ratio of 15 to 18 wt%, and St John's Wort added at a ratio of 15 to 18 wt%. Composition.
2. The method according to claim 1,

   The fragrance composition comprising the granule, the Angelica gigas, the raw paper, the granules, the granules, and the blisters suppresses the hyperactivity reaction that occurs when the user is exposed to nicotine during smoking cessation. Composition.
3. The method according to claim 1,

   The fragrance composition comprising the Seokchangpo, the Angelica gigas, the raw paper, the safflower, the safflower, and the blusher may be used to increase Brain-Derived Neurotrophic Factor (BDNF) expression in a user's brain cells to alleviate withdrawal symptoms Wherein the smoking cessation composition comprises at least one compound selected from the group consisting of:
4. (a) quantitatively measuring, crushing, and mixing the seokchonpo, Angelica gigas, Rhodochrosium spp.

   (b) filtering and filtering the mixture to a first set size;

   (c) extracting the supercritical oil for 7 to 9 hours at a pressure of 350 to 450 bar and a temperature of 55 to 65 캜;

   (d) cooling the supercritical oil at room temperature after allowing the supercritical oil to boil for 20 to 40 minutes at a temperature of 45 to 55 DEG C;

   (e) filtering and filtering at a second set size; And

   (f) filtering the mixture at a third set size, and then filtering the mixture through a paper filter to obtain a smell of perfume composition.

Images